Publications by authors named "Jose Zuzuarregui"

Research Question: What is the capability of serum anti-Müllerian hormone (AMH) measured using the automated Elecsys® AMH immunoassay to (Roche Diagnostics International Ltd) determine ovarian response after fertility treatment?

Design: Single-centre, retrospective, observational, cohort study including women undergoing ovarian stimulation. Serum AMH concentrations were determined using the Elecsys AMH immunoassay based on one blood sample drawn 6 months or less before treatment. Stimulation was conducted in accordance with a gonadotrophin-releasing hormone (GnRH) antagonist protocol.

View Article and Find Full Text PDF

Sleep disturbances are among the most common nonmotor complications of Parkinson's disease (PD), can present in prodromal stages, and progress with advancing disease. In addition to being a symptom of neurodegeneration, sleep disturbances may also contribute to disease progression. Currently, limited options exist to modulate sleep disturbances in PD.

View Article and Find Full Text PDF
Article Synopsis
  • Amantadine is a medication used for treating Parkinson's disease, but can cause side effects like myoclonus (sudden muscle jerks) and asterixis (tremors).
  • An 80-year-old man experienced worsening symptoms, including tremors and visual hallucinations, after starting amantadine, leading to the discovery of myoclonus and asterixis.
  • The patient's symptoms improved after reducing the dosage and ultimately discontinuing the medication, highlighting the need for careful monitoring by healthcare providers when prescribing amantadine.
View Article and Find Full Text PDF

Parkinson's disease (PD) is an alpha-synucleinopathy that leads to prominent motor symptoms including tremor, bradykinesia, and postural instability. Nonmotor symptoms including autonomic, neurocognitive, psychiatric symptoms, and sleep disturbances are also seen frequently in PD. The impact of PD on sleep is related to motor and nonmotor symptoms, in addition to the disruption of the pathways regulating sleep by central nervous system pathology.

View Article and Find Full Text PDF

Background: Parkinson's disease (PD) can have a significant impact on sleep. Deep brain stimulation (DBS) is an effective treatment for motor features of PD, but less is understood about the impact DBS may have on sleep architecture and various sleep issues commonly seen in PD.

Objective: To review the impact of DBS on various sleep issues in PD.

View Article and Find Full Text PDF

Background: Postural tachycardia syndrome (POTS) is an autonomic disturbance characterized by an excessive increase in heart rate when an individual moves from a sitting to an upright position. POTS patients often complain of fatigue, daytime sleepiness and insomnia, but there is limited evidence to elucidate the mechanism or the prevalence of sleep-related symptoms in POTS, as well as the effect on patient quality of life. Here, we investigated the prevalence of sleep disturbances in POTS patients, as well as the use of medication and effects on daily life.

View Article and Find Full Text PDF

Objective: We developed a program to promote medical student interest in pursuing a career in neurology. This program focuses on medical student mentorship. It also offers opportunities in teaching and clinical research in order to provide students with marketable skills for an academic career in neurology.

View Article and Find Full Text PDF

Study Question: What is the final hormonal milieu of pre-ovulatory follicles of low-responder (LR) patients undergoing unstimulated cycles?

Summary Answer: Neither androgen secretion nor LH was impaired in pre-ovulatory follicles of LR women.

What Is Known Already: Therapies currently used to improve ovarian response in LR women have an impact on the final hormonal follicular milieu, and these changes are believed to be partially responsible for determining the success rate in these women. Surprisingly, as far as we know, there is no report of the final hormonal profile of LR women undergoing unstimulated cycles or evidence that follicular androgen secretion in LR women is impaired.

View Article and Find Full Text PDF

Objective: To evaluate whether methotrexate (MTX) compromises ovarian reserve and future reproductive outcome in women undergoing assisted reproductive technology (ART), when it is used as first-line treatment for ectopic pregnancy (EP).

Design: Prospective, observational study.

Setting: University-affiliated private IVF unit.

View Article and Find Full Text PDF